MIA-T - Micro Interventional
The MIA-T procedure is intended to replicate a surgical annuloplasty procedure on the end of a catheter, reducing annular area and ultimately reducing tricuspid regurgitation. The animation on the left articulates the MIA-T procedure.
Micro Interventional Devices (MID) designs, manufactures and ...
MID develops products for Transcatheter Cardiac Repair (TCR) percutaneously replicating surgical procedures with the aim of eliminating the need for open heart surgery! Patient: Through less invasive and less morbid procedures. Surgeon/Interventionalist: Through technology that improves outcomes, reduces operative time and/or improves ease of use.
Clinical Trials | Micro Interventional
Micro Interventional Devices is preparing for a US Clinical Trial studying the safety and efficacy of the MIA-T system. The technology was granted FDA Breakthrough Designation in December 2019. The company anticipates receipt of approval to commence a US study in 2024.
Micro Interventional Devices MIA-T Tricuspid Annuloplasty …
May 27, 2021—Micro Interventional Devices (MID) has received FDA Breakthrough Device designation for its MIA-T percutaneous tricuspid minimally invasive annuloplasty system. The MIA-T system treats moderate-severe tricuspid regurgitation (TR) via a …
FDA Grants Micro Interventional Devices, Inc. Breakthrough Device ...
2021年5月27日 · MID develops proprietary Transcatheter Cardiac Repair (TCR) technologies addressing unmet needs in the treatment of structural heart disease. The company's products are designed to...
FDA Grants Micro Interventional Devices, Inc. Breakthrough
2021年5月27日 · The MIA-T system treats moderate-severe tricuspid regurgitation (TR) via a 12F catheter-based system. MID develops proprietary Transcatheter Cardiac Repair (TCR) technologies addressing unmet needs in the treatment of structural heart disease.
Mia T. - Senior Software Engineer - Apple | LinkedIn
Mia is an accomplished front-end developer with over 8 years of experience in designing and implementing robust, user-friendly, and high-performance web applications that serve hundreds of...
- 职位: Actively seeking Frontend, Full …
- 位置: Apple
- 500+ 连接数
The MIA-T Polymer-Based Percutaneous Tricuspid Annuloplasty …
2021年7月22日 · The MIA-T Polymer-Based Percutaneous Tricuspid Annuloplasty System: Technology Description and Early Human Clinical Data Presenter: Mathew Williams July 22, 2021
Micro Interventional Devices, Inc.™ Announces Submission of CE …
NEWTOWN, Pa., Jan. 28, 2021 /PRNewswire/ -- Micro Interventional Devices, Inc.™ (MID) announced today that it has submitted the required technical documentation for CE Mark approval for its MIA-T...
FDA Grants Micro Interventional Devices, Inc. Breakthrough Device ...
NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA™-T Percutaneous Tricuspid Annuloplasty System. The MIA-T system treats moderate-severe tricuspid regurgitation (TR)